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Temporal Trends in Mean Charges, Mortality, and LOS for Hospitalization for
PCI with or Without CVA
Mean Charges ($) Mean Mortality (%) Mean LOS (days)
CVA No CVA CVA No CVA CVA No CVA
1998 42954 24177 12.6 0.9 8.8 3.2
1999 45289 25686 15.0 0.9 8.7 3.0
2000 45895 27502 14.1 0.8 7.7 2.9
2001 50716 28650 14.0 0.8 8.2 2.8
2002 54756 33780 9.5 0.8 7.6 2.8
2003 65413 39178 8.9 0.7 7.8 2.8
2004 72841 44156 9.0 0.7 7.5 2.7
2005 78708 47785 9.5 0.7 7.7 2.7
2006 81468 48295 10.2 0.7 7.7 2.6
2007 95848 51552 10.5 0.8 8.3 2.7
2008 96081 55585 7.9 0.8 7.7 2.7
Mean 66361 38759 11.0 0.8 8.0 2.8
Table. One-Month Adverse Events Rates by Acute Kidney Injury Status
Tertile I, <7
(N = 854)
Tertile II, 7-12
(N = 825)
Tertile III, >12
(N = 948)
p-Value
for trend
Acute kidney injury (n[226)
MACE 3 (5.5) 7 (11.2) 21 (19.8) 0.04
NACE 7 (12.6) 13 (20.8) 37 (34.9) 0.006
No acute kidney injury (n[2042)
MACE 41 (6.0) 52 (8.1) 100 (14.0) <0.0001
NACE 68 (10.0) 74 (11.5) 139 (19.4) <0.0001
Data are Kaplan-Meier estimates and presented as n (%).
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The Ratio of Contrast Medium Dose and Estimated Glomerular Filtration
Predicts Contrast-induced Acute Kidney Injury among Patients for Elective
Percutaneous Coronary Intervention
Arnel G. Gabriel1, Dax Rinzi Sandoval1, Vonn P. Velasco1, Francisco P. Dalangin1
1St. Luke's Medical Center, Quezon City, Philippines
Background: The occurrence of contrast-induced acute kidney injury (CI-AKI)
among patients undergoing percutaneous coronary intervention (PCI), is proven to be
related to increased mortality and morbidity. Major risk factors such as advanced age,
diabetes and heart failure are often non-modiﬁable. Recent studies show that by
adjusting the contrast media (CM) dose, which is one of the few modiﬁable risk
factors, based on renal function reduces the incidence of CI-AKI. It is the objective of
this study to determine if CM dose, in grams of Iodine, to the estimated glomerular
ﬁltration rate ratio (g-I/eGFR) of greater than 1.42 predicts CI-AKI among patients
who underwent elective PCI.
Methods: This is a retrospective study of all adult patients, ages 18 years and above,
who underwent elective PCI from January 1, 2008 to September 30, 2012 in our
institution. The occurrence of CI-AKI is deﬁned as a >0.5mg/dl or >25% increase in
peak serum creatinine taken 48 to 72 hours after the procedure compared to the
baseline values.
Results: Out of 1376 patients, only 675 patients met the inclusion criteria and were
eligible for analysis. The prevalence of CI-AKI is 8.4%. A g-I/eGFR of >1.42
has a sensitivity of 79% and speciﬁcity of 80% in predicting CI-AKI, with a positive
and negative predictive values of 27% and 98%, respectively. Among patients with
g-I/eGFR of >1.42 who developed CI-AKI, the relative risk is 11.41 (p <0.0001),
furthermore those with diabetes, hypertension and left ventricular ejection fraction
(LVEF) of <45% have the relative risks of 9.98 (p <0.0001), 10.99 (p <0.0001)
and 4.28 (p 0.006), respectively. LVEF is predictive of CI-AKI, those with LVEF
of >45% has the best g-I/eGFR cut-off value of 1.42 based on ROC-AUC (0.841).
By deriving the contrast media dose from the g-I/GFR ratio of 1.42, we can be
guided to administer the safe limit of contrast volume during PCI: Contrast volume
(mL) ¼ (1.42 x eGFR) / 0.37g/mL where, 0.37g/mL – Iodine concentration of
contrast media
Conclusions: The ratio of CM dose to creatinine clearance is predictive of CI-AKI. A
g-I/eGFR ratio of <1.42 is a useful guide in limiting the contrast dose based on the
baseline eGFR values before an elective PCI.
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Temporal Trends in Hospital Charges and Resource Utilization for CVA
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Background: Cerebrovascular accident (CVA) subsequent to percutaneous coronary
intervention(PCI) is a severe complication. Little is known regarding the use of
healthcare resources and hospital charges associated with CVA. We analyzed
healthcare resource utilization and cost associated with CVA subsequent to PCI in the
USA from 1998-2008.
Methods: The Nationwide Inpatient Sample (NIS) was analyzed from 1998-2008.
The primary analysis was performed to assess the incremental hospital charges for
CVA subsequent to PCI. The secondary analysis was aimed to differentiate which
variables contributed to the incremental charges. Multivariate linear regression was
used to adjust for speciﬁc variables.
Results: There were 1,543,858 patients without CVA and 8,744 (0.56%) with CVA
who underwent PCI from 1998-2008 with no signiﬁcant trend (adjusted p for trend
0.2271). PCI-associated CVA had an incremental mean hospital charge of $28,564
($68,516 vs. $39,952, p<0.0001) along with an increased mortality (10.8% vs. 0.8%,
p<0.0001) and length of stay (LOS)(7.9 vs. 2.8 days, p<0.0001). Mortality in both
groups decreased over the study period; 12.58% to 7.88% (CVA, adjusted p for trend
0.0016) vs. 0.94% to 0.82% (no CVA, adjusted p for trend <0.0001). The average
hospital charges increased for both groups (adjusted p for trend <0.0001). The
increased cost with CVA was largely associated with an increased LOS, which
contributed $11,262(40%) to the cost. The LOS decreased for both groups over the
study period (adjusted p for trend <0.0001).B108 JACC Vol 62/18S1/Suppl B j OctobConclusions: The overall hospital charges for PCI-associated CVA increased from
1998-2008 with an associated decrease in mortality. The increased charges were
largely due to longer LOS. There was a signiﬁcant downward trend in LOS for both
groups.
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The SYNTAX Score Predicts Acute Kidney Injury After PCI for NSTEACS:
Analysis from the ACUITY Trial
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Background: The SYNTAX score (SS) has demonstrated prognostic utility for
ischemic outcomes in patients undergoing percutaneous coronary intervention (PCI)
for stable and unstable coronary syndromes. A recent study also found the SS to
be correlated with acute kidney injury (AKI) in patients with STEMI. The utility
of the SS to predict AKI after PCI in patients with NSTEACS has yet to be
investigated.
Methods: We stratiﬁed 2,627 patients in whom PCI was performed for NSTEACS
in the ACUITY trial into SS groups based on tertiles (SS <7, 7-12, and >12) trial.
AKI was deﬁned as a post-PCI increase in serum creatinine by 25% or 0.5 mg/dL.
We also assessed 30-day rates of major adverse cardiovascular events (MACE) and
net adverse clinical events (NACE; MACE or bleeding) by post-procedural AKI
status.
Results: A total of 226 (8.6%) patients developed AKI. Rates of AKI in the highest
ACUITY SS tertile (>12) were signiﬁcantly greater than in the intermediate (7-12)
and lowest tertiles (<7) (12.9% vs. 8.9%, p¼0.01 and 12.9% vs. 7.7%, p¼0.0009,
respectively). Thirty-day rates of MACE and NACE increased by SS tertile and were
more common in patients that developed AKI (Table). By multivariable analysis, the
SS was independently associated with AKI (HR per 10 SS points: 1.22, 95% CI: 1.04
to 1.43; p¼0.02).
Conclusions: The results of this large-scale study demonstrate that the SS is inde-
pendently associated with AKI after PCI for NSTEACS. In addition, the SS has
prognostic utility for MACE and NACE in this patient population independent of
whether AKI develops.er 27–November 1, 2013 j TCT Abstracts/POSTER/PCI Complications
